Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

Tools

Zhao, Sizheng Steven, Harrison, Stephanie R., Thompson, Ben, Yates, Max, Eddison, Joe, Chan, Antoni, Clarke, Nick, Corp, Nadia, Davis, Charlotte, Felix, Lambert, Flora, Kalveer, Gregory, William J., Jones, Gareth T., Lamb, Christopher A., Marzo-Ortega, Helena, Murphy, Daniel J., Petrushkin, Harry, Sandhu, Virinderjit, Sengupta, Raj, Siebert, Stefan, Van Der Windt, Danielle A., Webb, Dale, Yiu, Zenas Z. N. and Gaffney, Karl (2025) Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs. Rheumatology, 64 (6). pp. 3234-3241. ISSN 1462-0324

Preview

PDF (keaf090) - Published Version
Available under License Creative Commons Attribution.
Download (1MB) | Preview

Abstract

Background and rationale for guideline development: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the spine and sacroiliac joints [1]. It can also involve peripheral joints and entheses, and extra-musculoskeletal manifestations (EMMs) such as acute anterior uveitis, psoriasis and IBD. Since the previous version of the British Society for Rheumatology (BSR) axSpA guideline [2], which only included TNF inhibitors, pharmacological treatment options and strategies for axSpA have expanded, alongside rapid advancements in the treatment of EMMs as index conditions. In this increasingly complex and evolving therapeutic landscape, we aimed to update the guideline for health professionals in the UK who care for adults with axSpA.

Item Type:	Article
Additional Information:	Data availability: All data are provided in online Supplementary Materials, available at Rheumatology online. Funding: S.S.Z. was supported by a National Institute for Health and Care Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant nos. 21173, 21754 and 21755) and the NIHR Manchester Biomedical Research Centre (NIHR203308). C.A.L. was supported by the NIHR Newcastle Biomedical Research Centre. H.M.O. was supported by the NIHR Leeds Biomedical Research Centre (Leeds BRC). Z.Y. is supported by a Medical Research Council Clinician Scientist Fellowship (MR/Z504026/1). The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. L.F., N.C., D.v.d.W. were funded by BSR to perform the literature review.
Uncontrolled Keywords:	axspa, ankylosing spondylitis,biologics,extra-musculoskeletal manifestations,guideline,inflammatory bowel disease,management,psoriasis,recommendations,targeted synthetic dmards,treatment,uveitis,rheumatology,pharmacology (medical) ,/dk/atira/pure/subjectarea/asjc/2700/2745
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Centres > Public Health Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	02 Sep 2025 14:30
Last Modified:	02 Sep 2025 14:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/100267
DOI:	10.1093/rheumatology/keaf090

Downloads

Downloads per month over past year

Actions (login required)

View Item